JUN 26, 2021 8:27 AM PDT

Immunotherapy Drug Shows Promise for Obese Patients with Breast Cancer

WRITTEN BY: Annie Lennon

Research shows that obese patients with cancers including ovarian and melanoma may respond better to a certain kind of immunotherapy than non-obese patients. Now, researchers from the University of Tennessee Health Science Center have set out to find whether this is also true for obese patients with breast cancer. 

The immunotherapy drug investigated is known as a checkpoint inhibitor. Checkpoint inhibitors work by transferring substances to the body that prevent tumor cells from switching off tumour-fighting cells, and thus allow the immune system to defend itself. 

In 2019 and 2020, two immune checkpoint inhibitors known as atezolizumab (an anti-PD-L1 inhibitor) and pembrolizumab (an anti-PD-1 inhibitor) were approved to treat some patients with triple-negative breast cancer, a highly aggressive form of the disease. 

Obesity can cause many complexities due to its ability to both cause inflammation and activate inflammatory pathways that suppress the immune system. As such, patients with obesity tend to have worse outcomes to breast cancer treatments than non-obese patients. 

For the present study, the researchers set out to find how checkpoint inhibitors could work in obese patients with breast cancer. To do so, they studied models of breast cancer in both obese and lean mice. In doing so, they found that tumors grew at a faster pace among obese mice than in their lean counterparts. 

They also found that anti-PD-1 immune checkpoint blockade (ICB) was able to successfully block obesity-driven progression of cancer. ICB also increased immune cell numbers with anti-tumor immunity and effective anti-tumor markers. These results were reported both in mice both with and without obesity. 

“Importantly, anti-PD-1 therapy had no impact on weight or body composition throughout the study, which rules out confounding effects of therapy-induced weight loss," write the researchers in their paper. 

"This study emphasizes the complexity of examining immunotherapy in immune-competent mice with consideration of the natural variance in weight gain, tumor growth, innate regression, and response to ICB.”

While promising results, the researchers nevertheless say that future studies should match mouse models in tumor size to allow for more controlled comparisons. They also said that their study was limited as it did not examine additional outcomes including survival, recurrence after removal of therapy and metastasis, all of which are critical factors for patient care. 

 

Sources: Medical XpressCell Reports

About the Author
  • Annie Lennon is a writer whose work also appears in Medical News Today, Psych Central, Psychology Today, and other outlets. When she's not writing, she is COO of Xeurix, an HR startup that assesses jobfit from gamified workplace simulations.
You May Also Like
SEP 09, 2021
Cancer
Can a Mole Fight Melanoma?
SEP 09, 2021
Can a Mole Fight Melanoma?
About 30% of melanoma cases arise from an existing nevus.  More commonly known as moles, Nevi are skin growths that ...
OCT 04, 2021
Cancer
Good News for Coffee Lovers: A New Study Finds Caffeine Does Not Impact Breast Cancer Risk
OCT 04, 2021
Good News for Coffee Lovers: A New Study Finds Caffeine Does Not Impact Breast Cancer Risk
Reports indicate that caffeine consumption in the United States is greatest in adults aged 50 – 64.  Coincide ...
OCT 28, 2021
Cancer
NF-κB: a Trick or a Treat for Cancer?
OCT 28, 2021
NF-κB: a Trick or a Treat for Cancer?
A family of proteins, known as transcription factors, regulate the biological process of converting DNA into RNA. T ...
OCT 24, 2021
Microbiology
New Treatment Approach Uses Bacteria to Deliver Drugs to Cancer Cells
OCT 24, 2021
New Treatment Approach Uses Bacteria to Deliver Drugs to Cancer Cells
Bacteria can be found almost everywhere, and they can serve many beneficial purposes. Scientists are now using bacterial ...
NOV 14, 2021
Genetics & Genomics
Cancer Drug Target Could Actually Worsen Disease
NOV 14, 2021
Cancer Drug Target Could Actually Worsen Disease
Cancer drugs have been developed that target an enzyme, Shp2. But that enzyme has a more complex role than we knew.
DEC 18, 2021
Cell & Molecular Biology
How the HTLV-1 Virus Can Turn Immune Cells Cancerous
DEC 18, 2021
How the HTLV-1 Virus Can Turn Immune Cells Cancerous
In some cases, viruses have been linked to cancer. For example, HPV, which is now preventable with a vaccine, can lead t ...
Loading Comments...